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A B S T R A C T
The aim of this study was to gain insight of the breast cancer hormone receptor status of our patients, its stratification
according to age as well as its changes during the period of 13 years. 11,273 patients with primary breast cancer from
several towns in Croatia were included in this study. Patients’ tumour specimens were collected from 1990 to 2002 and
were analysed on estrogen (ER) and progesterone (PR) receptors in the Laboratory of the Department of Medical Oncol-
ogy, University Hospital Centre Zagreb. More than half of our breast cancer patients had ER positive tumours (54.3%).
We observed ER+ tumours increased with age continuously, with highest percentage in the age group of 70 to 79 years
(68.1%). Similarly, proportion of PR+ tumours was higher in the older age groups, being the highest between 40 and 49
years (55.9%). During 13 years of the study, the increase in frequency and proportion of ER+ tumours was observed
(from 52% in 1990 to 62% in 2002) and decrease of PR+ tumours (56% to 53%). We confirm previous findings that the
risk of hormone dependent breast cancer increases with aging. Risk of ER+ breast cancer increased for 10% from 1990 to
2002 and PR+ tumours decreased for 3.5% in the same period.
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Introduction
Breast cancer hormone receptor status suggests dif-
ferent biological and clinical profiles. ER positive tu-
mours are more likely to be histological well-differenti-
ated, diploid and have a lower S phase fraction. ER
positivity is also associated with increasing age, post-
menopausal status and is an independent factor of better
prognosis.
In our study we analysed distribution of breast cancer
hormone receptor status according to age groups of pa-
tients as well as overall and age stratified hormone re-
ceptor status of our patients from the year 1990 to 2002.
The results presented in this paper are from a single
centre study on 11,273 patients with primary breast can-
cer treated in hospitals in several towns in Croatia. The
tumour specimens were collected from the year 1990 to
2002 and analysed on ER and PR in the Laboratory of
the Department of Medical Oncology, University Hospi-
tal Centre Zagreb, thus eliminating the variations in the
results due to interlaboratory methodological differenc-
es. The results are comparable to other European cen-
tres, as the Laboratory is included in the EORTC recep-
tor study group.
Patients and Methods
Patients
The breast cancer patients included in this study
were treated in hospitals in several towns of Croatia. The
age distribution of patients was as follows: 28% of pa-
tients were of 60 to 69 years of age, 24% were aged 50 to
59, 19% 40 to 49 as well as 70 to 79 years, and in the age
group of 20 to 39 years there were 6% of patients, while
4% of patients were older than 80 years.
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Methods
Tumour tissue specimens were placed on ice immedi-
ately after excision during biopsy or mastectomy and
within 30 minutes were frozen in liquid nitrogen. The
specimens were then sent to the laboratory and stored
until assayed, for not longer than 3 weeks.
The ER and PR were measured by a point assay using
the dextran- coated charcoal method based on that of
Horwitz and McGuire1, modified as described previo-
usly2. Tumour cytosol containing 1–2 mg/ml protein
(measured by Lowry’s method) was incubated in tripli-
cate at 4°C for 18 hours with appropriate radioactively la-
belled ligands, with or without »cold» competitors, as fol-
lows: for ER with 3H- oestradiol in final concentration of
0.8 nmol/l without and with 100 fold excess of diethylstil-
bestrol; for PR with 3H-promegestone (R5020) in final
concentration of 8.0 nmol/l in the presence of a 100 fold
excess of cortisol and without or with a 100 fold excess of
»cold« R5020. Cortisol was added to prevent the binding
of R5020 to glucocorticoid receptors. It was found that in
these conditions (protein, ligand and competitor concen-
trations) one point assay for both ER and PR were in
good correlation with multipoint assays3–7.
The tumours with a binding capacity higher than 10
fmol/mg cytosol protein for estradiol and R5020 were
considered receptor positive.
Results
In the study we observed that more than half of our
breast cancer patients had estrogen receptor positive tu-
mours. The most frequent subtype of tumour was ER+
PR+ involving 34.3% of all cases, followed by ER-PR-
subtype with 27.8%, ER+PR- with 20.2%, and ER-PR+
with 17.7%. These results are comparable to those of the
US study on 5,993 breast cancer patients8.
Comparing estrogen receptor status of tumours to pa-
tients’ age showed that the frequency of ER+ tumours
(ER+ PR+ and ER+ PR-) increased with age continually
with a decrease around age of 80. Highest percentage of
ER + tumours was in the age of 70 to 79 – with 68.1%,
and the age group of 80 years and older followed with
64.8% of ER+ tumours. Patients with 69 years and youn-
ger had progressively lower percentage of ER+ tumours.
Similarly, proportion of PR+ tumours was higher in
older age groups, being the highest between 40 and 49
years of age. As concerns ER- tumours the frequency of
ER- PR+ subtype decreased with age prior to age 80 and
afterwards increased. Subtype of ER- PR- tumours de-
creased continually with age (Figure 1).
These findings are similar to the results of compara-
ble studies of ER PR age distribution among 3,359
Danish9 and 110,010 US10 breast cancer patients.
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Fig. 2. Diagram illustrating number of patients with different tumour subtypes and total number of breast cancer patients in each year
of the study. ER – estrogen receptor, PR – progesterone receptor.
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Fig. 1. Proportion of different breast cancer subtypes (according
to hormone receptor status) in different age groups. The risk of
hormone dependent breast cancer increases with age. ER – estro-
gen receptor, PR – progesterone receptor.
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During the period of 13 years (1990–2002) we fol-
lowed the frequency and proportion of ER+ and ER-,
PR+ and PR- tumours as well as their combinations
(Figures 2 and 3). We observed an overall increase of
ER+ tumours among breast cancer patients. More pre-
cisely the proportion of ER+ tumours declined from year
1990 (52%) to 1996 (44%) and then had a constant in-
crease until 2002 (62%) (Figure 4), alternatively propor-
tion of ER negative tumours changed correspondingly.
As concerns frequency of ER+ tumours, after an in-
crease in number of cases in the first 7 years of follow up,
it declined below the initial number. Stratifying ER+
breast cancer patients in different age groups and follow-
ing their proportions during 13 years we found that
trend of increase of ER+ tumours was present in all age
groups (Table 1 and 2).
Overall, the proportion of women diagnosed with PR
positive tumours, as well as their number, decreased over
the study period. Initially 56% of tumours were PR+, in
1996 45% and 2002 53% (Figure 5). Stratifying these re-
sults into age groups we found the decline of PR+ tu-
mours was present in age groups 20 to 39 and older than
80. In other age groups the proportion of PR+ tumours
remained constant during 3 years (Table 1 and 3).
Analysing different subtypes of breast cancer accord-
ing to ER and PR status we observed overall increase in
proportion of ER+PR+ and ER+ PR- tumours from 37%
to 38% and 15% to 24%, respectively over 13 years. Alter-
natively percentage of ER-PR- and ER-PR+ tumour sub-
types decreased during the same period from 28% to 22%
and 19% to 15%, respectively (Figure 3). Differences by
age were observed, as ER+PR+ tumours increased only
among 20- to 49-year-olds and aged 80 and older in the
period of 13 years (Table 1). Also, ER+PR- tumours in-
creased in all age groups but 40 to 49-year-olds (Table 2).
ER-PR+ tumours decreased among every age group but
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Fig. 3. Diagram showing how distribution of breast cancer sub-
types (percentage) changes over the period of 13 years. ER – estro-
gen receptor, PR – progesterone receptor.
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Fig. 4. Changes of proportion of estrogen receptor positive breast
cancer during the period of study (13 years). ER – estrogen recep-
tor, PR – progesterone receptor.
TABLE 1
PROPORTION OF BREAST CANCER PATIENTS WITH ESTROGEN AND PROGESTERONE RECEPTOR POSITIVE TUMOURS
STRATIFIED IN DIFFERENT AGE GROUPS IN THE PERIOD OF 13 YEARS
Year
Age groups of ER+PR+ breast cancer patients
<20 20–39 40–49 50–59 60–69 70–79 80+
1990 0% 24.4% 28.8% 36.1% 41.0% 52.6% 36.0%
1991 0% 21.1% 25.0% 34.2% 38.7% 38.0% 34.8%
1992 0% 31.3% 29.0% 31.4% 41.3% 50.4% 53.9%
1993 0% 25.8% 30.0% 34.6% 39.0% 44.8% 35.1%
1994 0% 23.9% 27.1% 33.3% 44.6% 51.2% 45.5%
1995 0% 20.5% 29.4% 28.6% 33.6% 36.8% 47.4%
1996 0% 4.7% 18.4% 23.1% 27.1% 35.9% 40.0%
1997 0% 24.5% 29.3% 28.5% 41.5% 42.2% 50.0%
1998 0% 23.5% 32.0% 29.4% 41.9% 42.3% 35.8%
1999 0% 11.3% 22.7% 28.6% 29.3% 39.8% 39.6%
2000 0% 19.4% 27.5% 26.8% 34.4% 36.8% 39.3%
2001 100% 29.3% 42.4% 42.9% 46.3% 48.3% 28.1%
2002 0% 27.6% 34.7% 25.3% 42.0% 48.0% 42.2%
ER – estrogen receptor, PR – progesterone receptor
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70 to 79 (Table 3). Decrease of ER-PR- tumours over time
was limited to women aged 50 and older (Table 4).
We should mention that there were no changes in
methodology of hormone receptor status determination,
which could influence our findings and effects we ob-
served.
Discussion
Characterisation of breast tumours on both ER11 and
PR status suggests different biological and clinical pro-
files. ER positive tumours are more likely to be his-
tological well-differentiated, diploid and have a lower S
phase fraction12. ER positivity is also associated with in-
creasing age and postmenopausal status, and is nega-
tively correlated with tumour size13,14. ER status remains
an independent factor of prognosis. Therefore presence
of functional ER serves as a marker of differentiation
and a predictor of disease-free survival in node-negative
and node positive breast cancer patients14,15. Apart from
biological and clinical characteristics of breast cancer ER
and PR status may define fundamental types of breast
tumours16 with different risk factors and therefore dif-
ferent aetiologies. ER+PR+ tumours were associated
with risk factors such as parity, age at first birth, age at
menarche, body mass index and body fat distribution.
ER- PR- and ER+PR- breast cancers showed inverted
pattern of associations with several risk factors of ER+PR+
tumours – parity and waist to hip ratio for ER-PR-, his-
tory of bilateral oophorectomy and oral contraceptive use
for ER+PR-, body mass index for ER+PR- and ER-
-PR-17. Considering the facts on the role of breast cancer
hormone dependency in its aetiology and biology we ex-
amined whether age-specific risk of breast cancer, espe-
cially its change at menopause, differs by oestrogen and
progesterone receptor status.
Our study showed stratification of ER PR breast can-
cer status by age. The risk of hormone dependent breast
cancer increased with aging. Before menopause (age of
50) the majority of tumours were estrogen receptor nega-
tive (67% of all tumours in the younger age group (20–39
years) and 60% in the older (40–49 years)). Increasing
risk of ER positive tumours started around menopause –
at the age of 50 and later, when they made 50% to 68% of
all cases, the highest frequency between the ages 70 to
79. These results match those of two studies – US10 and
Danish9 which revealed substantially higher risk of
ER+PR+ tumour subtype with increasing age.
Further comparison of our findings to Danish9, US
white10 and Japanese18 female populations showed follow-
ing results. Substantially higher risk of ER+ PR+ subtype
was evident in US (64.2% of all cases) and Danish (62.9%)
compared to Croatian (34.34%) and Japanese (29%) female
population. The risk difference appeared to increase with
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TABLE 2
PROPORTION OF BREAST CANCER PATIENTS WITH ESTROGEN RECEPTOR POSITIVE AND PROGESTERONE RECEPTOR
NEGATIVE TUMOURS STRATIFIED IN DIFFERENT AGE GROUPS IN THE PERIOD OF 13 YEARS
Year
Age groups of ER+PR- breast cancer patients
<20 20–39 40–49 50–59 60–69 70–79 80+
1990 0% 4.4% 14.1% 14.6% 20.1% 15.5% 12.0%
1991 0% 9.9% 10.3% 15.2% 17.3% 18.0% 21.7%
1992 0% 9.4% 13.8% 19.1% 24.4% 21.0% 15.4%
1993 0% 9.7% 11.3% 14.8% 25.4% 32.4% 10.8%
1994 0% 8.7% 9.7% 15.9% 22.5% 23.3% 33.3%
1995 0% 15.9% 6.7% 20.2% 24.9% 18.4% 23.7%
1996 0% 14.1% 11.4% 20.6% 27.1% 13.8% 23.3%
1997 0% 15.1% 14.4% 23.2% 24.4% 29.2% 25.0%
1998 0% 7.8% 13.6% 23.1% 24.0% 31.4% 11.3%
1999 0% 12.9% 7.2% 19.1% 27.3% 22.8% 27.1%
2000 0% 12.9% 13.0% 29.3% 29.6% 31.0% 25.0%
2001 0% 31.0% 6.8% 18.0% 23.4% 25.5% 53.1%
2002 0% 10.3% 10.5% 27.4% 26.0% 28.0% 31.1%
ER – estrogen receptor, PR – progesterone receptor
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Fig. 5. Changes of proportion of progesterone receptor positive
breast cancer during the period of study (13 years). ER – estrogen
receptor, PR – progesterone receptor.
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age in former three populations. Age differences across
populations did not explain the differences in ER PR distri-
bution: ER+PR+ subtype in the Danish case-series strati-
fied by menopausal status was 62% in premenopausal, 57%
in perimenopause and 64% in postmenopausal women, all
of which were higher than the 29% in the Japanese case-se-
ries and Croatian (where this subtype was distributed into
24%, 30% and 40% respectively).
Our findings showed that proportion of ER+ PR+ and
ER+ PR- tumours had continuous rise towards older age
with slowing rate at the age of 80. The opposite is true for
ER-PR- tumours (Figure 1). Compared to our study, the
large Danish dataset showed incidence rates of the
ER+PR+ subtype had constant rate of increase with age,
similar to that of ER+PR- subtype which had rapid in-
crease in perimenopausal period, while those of ER-PR+
and ER-PR- decreased or remained unchanged after me-
nopause. In the US study for both white and black women
the age-specific rates of ER- breast cancer ceased increas-
ing after 50 years of age, but age-specific rates of ER+
breast cancer continue to increase after 50 years of age.
From 1990 to 2002 ER+ tumours in our population of
patients increased for 10% (in all age groups), and PR+
decreased 3.5% (in age groups 20 to 49 years of age and 80
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TABLE 4
PROPORTION OF BREAST CANCER PATIENTS WITH ESTROGEN AND PROGESTERONE RECEPTOR NEGATIVE TUMOURS
STRATIFIED IN DIFFERENT AGE GROUPS IN THE PERIOD OF 13 YEARS
Year
Age groups of ER-PR- breast cancer patients
<20 20–39 40–49 50–59 60–69 70–79 80+
1990 0% 33.3% 31.1% 30.2% 23.5% 24.1% 28.0%
1991 0% 38.0% 33.3% 30.4% 30.6% 26.0% 13.0%
1992 0% 26.6% 30.3% 30.4% 21.3% 20.2% 23.1%
1993 0% 48.4% 28.7% 31.3% 24.9% 13.3% 35.1%
1994 0% 39.1% 30.6% 33.9% 19.8% 14.7% 18.2%
1995 0% 29.6% 30.3% 33.9% 24.5% 32.4% 13.2%
1996 0% 48.4% 38.9% 33.3% 31.1% 24.3% 20.0%
1997 0% 39.6% 34.6% 34.2% 22.2% 17.7% 10.4%
1998 0% 45.1% 26.7% 30.9% 23.7% 19.1% 26.4%
1999 0% 41.9% 42.0% 35.7% 30.1% 25.7% 27.1%
2000 0% 38.7% 33.6% 26.2% 23.3% 21.3% 25.0%
2001 0% 33.3% 30.5% 23.6% 18.6% 15.4% 9.4%
2002 0% 41.4% 35.8% 26.7% 19.9% 12.0% 17.8%
ER – estrogen receptor, PR – progesterone receptor
TABLE 3
PROPORTION OF BREAST CANCER PATIENTS WITH ESTROGEN RECEPTOR NEGATIVE AND PROGESTERONE RECEPTOR
POSITIVE TUMOURS STRATIFIED IN DIFFERENT AGE GROUPS IN THE PERIOD OF 13 YEARS
Year
Age groups of ER-PR+ breast cancer patients
<20 20–39 40–49 50–59 60–69 70–79 80+
1990 0% 37.8% 26.0% 19.0% 15.0% 7.8% 24.0%
1991 0% 31.0% 31.4% 20.3% 13.3% 18.0% 30.3%
1992 0% 32.8% 26.9% 19.1% 12.9% 8.4% 7.7%
1993 0% 16.1% 30.0% 19.2% 10.7% 9.5% 18.9%
1994 0% 28.3% 32.6% 16.9% 13.1% 10.9% 3.0%
1995 0% 34.1% 33.6% 17.3% 17.0% 12.5% 15.8%
1996 0% 32.8% 31.4% 23.1% 14.7% 9.4% 16.7%
1997 100% 20.8% 21.8% 14.2% 12.0% 10.9% 14.6%
1998 0% 23.5% 27.7% 16.7% 10.4% 7.3% 26.4%
1999 0% 33.9% 28.2% 16.6% 13.3% 11.7% 6.3%
2000 0% 29.0% 26.0% 17.7% 12.7% 11.0% 10.7%
2001 0% 7.1% 20.3% 15.5% 11.7% 10.7% 9.4%
2002 0% 20.7% 19.0% 20.6% 12.2% 12.0% 8.9%
ER – estrogen receptor, PR – progesterone receptor
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and older). Similar rise of ER+ tumours proportion was
presented in the US study19 following patients from 1992
to 1998. The former study also reported increase of PR+
tumours. This increase of hormone receptor positive tu-
mours seemed to be limited to women 40 to 69 years of
age. It also showed that incidence rates rose for ER+ and
PR+, but remained constant for ER- and PR- tumours.
Therefore the overall rise in breast cancer incidence rates
in the United States20 seemed to be primarily the result of
increase in the incidence of hormone receptor positive tu-
mours. Hormonal factors may have accounted for this
trend, according to their study. It was connected to higher
use of hormone replacement therapy, mean BMI increas-
ing, the mean age of menarche decreasing, and increasing
number of women in the US who are nulliparous and
older when they have their first live birth.
Conclusion
In our study we observed ER+ tumours increased
with age continuously, with highest percentage in the age
group of 70 to 79 years. Similarly, proportion of PR+ tu-
mours was higher in the older age groups, being the
highest between 40 and 49 years. These results match
those of two studies – US10 and Danish9 which revealed
substantially higher risk of ER+PR+ tumour subtype
with increasing age.
During 13 years of the study, we detected the trend of
increase in frequency and proportion of ER+ tumours
(for 10%) and the decrease of PR+ tumours (for 3,5%).
The trend of ER+ tumours was comparable to that of the
US study19.
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STATUS ESTROGENSKIH I PROGESTERONSKIH RECEPTORA KOD PRIMARNOG KACINOMA
DOJKE: ISTRA@IVANJE NA 11 273 PACIJENTICE OD 1990. DO 2002. GODINE
S A @ E T A K
Cilj ovog rada je istra`iti status hormonskih receptora karcinoma dojke kod na{ih pacijentica, stratificirati ih prema
dobi, te utvrditi mijenja li se status receptora tijekom 13 godina pra}enja pacijentica. U istra`ivanje je bilo uklju~eno 11
273 pacijentica s primarnim karcinomom dojke, iz nekoliko gradova Hrvatske. Uzorci tumora prikupljani su od 1990.
do 2002. godine, te je u~injena analiza statusa estrogenskih i progesteronskih receptora u Laboratoriju Zavoda za pato-
fiziologiju, Klini~kog bolni~kog centra Zagreb. Ve}ina pacijentica imala je pozitivne estrogenske receptore u tumoru
(54,3%). Uo~ili smo kontinuirani porast u~estalosti estrogen pozitivnih tumora s dobi, s najvi{om u~estalosti u dobnoj
skupini od 70 do 79 godina (68,1%). Sli~no, udio progesteron pozitivnih tumora raste s dobi, te je najvi{i izme|u 40 i 49
godina (55,9%). Tijekom 13 godina istra`ivanja, uo~en je porast broja i postotka estrogen pozitivnih tumora (s 52%
1990.g. na 62% 2002.g.) te smanjenje progesteron pozitivnih tumora (s 56% na 53%). Ovim istra`ivanjem potvr|eni su
rezultati ranijih studija kojima je utvr|en porast hormon ovisnih tumora s dobi. Rizik estrogen pozitivnih karcinoma
dojke porastao je od 1990.g. do 2002.g. za 10%, dok se rizik progesteron pozitivnih smanjio za 3,5%.
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